Last reviewed · How we verify

NCT05520112

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Status unknown Phase 1, PHASE2 Last updated 29 August 2022
What this trial tests

Phase 1, PHASE2 trial testing Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction in Recurrent Pregnancy Loss in 20 participants. Status unknown.

Timeline
1 November 2022
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
PhasePhase 1, PHASE2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 November 2022
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across Belarus

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Who can join

Adults 18 to 49, female only, with Recurrent Pregnancy Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Dual Role of Natural Killer Cells in Early Pregnancy: Immunopathological Implications and Therapeutic Potential in Recurrent Spontaneous Abortion and Recurrent Implantation Failure.
    Guan D, Chen Z, Zhang Y, Sun W, et al · · 2025 · cited 7× · PMID 40325291 · DOI 10.1111/cpr.70037

Verify or expand the search:

Other recruiting trials for Recurrent Pregnancy Loss

Currently open trials in the same condition.

Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing